To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Illumina to Conduct Custom Genotyping for J&J Pharmaceutical Research & Development
Illumina, Inc. has announced that it has signed a genotyping services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD).
Under the terms of the agreement, Illumina will develop custom SNP content for a multi-sample Sentrix® BeadChip.
The BeadChip platform is designed to enable analysis of 12 samples and up to 60,000 SNPs per sample on a single BeadChip.
Illumina expects to genotype thousands of samples provided by J&JPRD using its Infinium™ assay, which can provide array-based deployment and genotyping of virtually any SNP on the genome at effectively unlimited multiplex levels while delivering industry-leading data quality.
